Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 12 | 2024 | 73 | 4.380 |
Why?
|
| Students, Pharmacy | 9 | 2024 | 73 | 2.580 |
Why?
|
| Anticoagulants | 5 | 2024 | 15 | 2.010 |
Why?
|
| Analgesics, Opioid | 7 | 2024 | 74 | 1.630 |
Why?
|
| Pharmacy | 4 | 2023 | 16 | 1.330 |
Why?
|
| Humans | 36 | 2024 | 5477 | 1.320 |
Why?
|
| Emotional Intelligence | 3 | 2024 | 15 | 1.130 |
Why?
|
| Curriculum | 5 | 2024 | 50 | 1.110 |
Why?
|
| Pharmaceutical Services | 3 | 2023 | 18 | 1.080 |
Why?
|
| Faculty | 3 | 2023 | 15 | 1.040 |
Why?
|
| Schools, Pharmacy | 6 | 2023 | 24 | 0.850 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 6 | 0.810 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2022 | 6 | 0.740 |
Why?
|
| Atrial Fibrillation | 5 | 2024 | 15 | 0.730 |
Why?
|
| Hemodynamic Monitoring | 1 | 2021 | 1 | 0.700 |
Why?
|
| Preceptorship | 1 | 2020 | 4 | 0.670 |
Why?
|
| Social Desirability | 1 | 2020 | 4 | 0.670 |
Why?
|
| Hypolipidemic Agents | 1 | 2020 | 1 | 0.670 |
Why?
|
| Dicarboxylic Acids | 1 | 2020 | 4 | 0.660 |
Why?
|
| Fatty Acids | 1 | 2020 | 11 | 0.660 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 8 | 0.660 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 13 | 0.650 |
Why?
|
| Stroke Volume | 1 | 2020 | 13 | 0.640 |
Why?
|
| Hypnotics and Sedatives | 2 | 2024 | 10 | 0.640 |
Why?
|
| Heart Rate | 1 | 2020 | 43 | 0.630 |
Why?
|
| Pyridones | 2 | 2024 | 8 | 0.620 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 2 | 0.620 |
Why?
|
| Heart Failure | 1 | 2020 | 32 | 0.620 |
Why?
|
| Pyrazoles | 2 | 2024 | 19 | 0.620 |
Why?
|
| Pipecolic Acids | 2 | 2019 | 9 | 0.560 |
Why?
|
| Medication Adherence | 3 | 2024 | 70 | 0.540 |
Why?
|
| Retrospective Studies | 8 | 2024 | 382 | 0.520 |
Why?
|
| Critical Care | 1 | 2016 | 12 | 0.510 |
Why?
|
| United States | 8 | 2024 | 521 | 0.480 |
Why?
|
| Pain, Postoperative | 3 | 2024 | 6 | 0.460 |
Why?
|
| Patient Discharge | 3 | 2024 | 17 | 0.460 |
Why?
|
| Propofol | 1 | 2014 | 1 | 0.430 |
Why?
|
| Dexmedetomidine | 1 | 2014 | 2 | 0.430 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 6 | 0.430 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 10 | 0.430 |
Why?
|
| Pharmacy Residencies | 1 | 2013 | 3 | 0.420 |
Why?
|
| beta-Alanine | 1 | 2013 | 2 | 0.410 |
Why?
|
| Morpholines | 1 | 2013 | 3 | 0.410 |
Why?
|
| Thiophenes | 1 | 2013 | 6 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 47 | 0.410 |
Why?
|
| Pharmacists | 3 | 2023 | 41 | 0.410 |
Why?
|
| Benzimidazoles | 1 | 2013 | 10 | 0.410 |
Why?
|
| Thrombin Time | 1 | 2013 | 1 | 0.400 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 1 | 0.400 |
Why?
|
| Leadership | 2 | 2024 | 15 | 0.400 |
Why?
|
| Educational Measurement | 3 | 2024 | 49 | 0.390 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 7 | 0.380 |
Why?
|
| Rivaroxaban | 2 | 2024 | 6 | 0.320 |
Why?
|
| Stroke | 2 | 2024 | 53 | 0.300 |
Why?
|
| Faculty, Pharmacy | 2 | 2020 | 11 | 0.290 |
Why?
|
| Adult | 7 | 2024 | 1683 | 0.290 |
Why?
|
| Male | 9 | 2024 | 2765 | 0.290 |
Why?
|
| Arginine | 2 | 2019 | 7 | 0.250 |
Why?
|
| Sulfonamides | 2 | 2019 | 8 | 0.250 |
Why?
|
| Treatment Outcome | 2 | 2020 | 212 | 0.250 |
Why?
|
| Aged | 5 | 2024 | 859 | 0.240 |
Why?
|
| Physicians | 2 | 2023 | 18 | 0.240 |
Why?
|
| School Admission Criteria | 3 | 2023 | 10 | 0.240 |
Why?
|
| Middle Aged | 6 | 2024 | 1098 | 0.240 |
Why?
|
| Female | 8 | 2024 | 2811 | 0.230 |
Why?
|
| Electronic Health Records | 1 | 2024 | 18 | 0.220 |
Why?
|
| Factor Xa Inhibitors | 1 | 2024 | 5 | 0.220 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 8 | 0.220 |
Why?
|
| Markov Chains | 1 | 2024 | 18 | 0.220 |
Why?
|
| Pandemics | 2 | 2023 | 82 | 0.220 |
Why?
|
| Mentoring | 1 | 2024 | 13 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 20 | 0.220 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 17 | 0.220 |
Why?
|
| Academic Performance | 1 | 2024 | 20 | 0.220 |
Why?
|
| Life Change Events | 2 | 2023 | 18 | 0.210 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 6 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 23 | 0.200 |
Why?
|
| Community Pharmacy Services | 1 | 2023 | 8 | 0.200 |
Why?
|
| Prescription Drug Misuse | 1 | 2023 | 9 | 0.200 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 35 | 0.180 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 1 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 320 | 0.170 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 14 | 0.170 |
Why?
|
| Hemodynamics | 1 | 2021 | 18 | 0.170 |
Why?
|
| Pharmacies | 1 | 2020 | 3 | 0.170 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 1 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 2 | 0.170 |
Why?
|
| Primary Prevention | 1 | 2020 | 3 | 0.170 |
Why?
|
| Aspirin | 1 | 2020 | 4 | 0.170 |
Why?
|
| Minority Groups | 1 | 2020 | 39 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 284 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2020 | 16 | 0.160 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2020 | 1 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 44 | 0.160 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 1 | 0.160 |
Why?
|
| Warfarin | 1 | 2019 | 3 | 0.150 |
Why?
|
| Interviews as Topic | 1 | 2018 | 24 | 0.140 |
Why?
|
| Pulmonary Embolism | 2 | 2019 | 4 | 0.140 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 4 | 0.140 |
Why?
|
| Risk Factors | 2 | 2020 | 184 | 0.140 |
Why?
|
| Online Systems | 1 | 2016 | 4 | 0.130 |
Why?
|
| Problem-Based Learning | 1 | 2016 | 6 | 0.130 |
Why?
|
| Hydrocodone | 1 | 2016 | 3 | 0.130 |
Why?
|
| Controlled Substances | 1 | 2016 | 4 | 0.130 |
Why?
|
| Internet | 1 | 2016 | 35 | 0.130 |
Why?
|
| Specialization | 1 | 2014 | 1 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2014 | 2 | 0.110 |
Why?
|
| Texas | 3 | 2023 | 190 | 0.110 |
Why?
|
| Data Collection | 1 | 2014 | 15 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2014 | 1 | 0.110 |
Why?
|
| Infusions, Parenteral | 1 | 2014 | 2 | 0.110 |
Why?
|
| Length of Stay | 1 | 2014 | 7 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2014 | 9 | 0.110 |
Why?
|
| Delirium | 1 | 2014 | 7 | 0.110 |
Why?
|
| Medicare Part C | 2 | 2024 | 31 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2014 | 17 | 0.110 |
Why?
|
| Dabigatran | 1 | 2013 | 2 | 0.100 |
Why?
|
| Drug Prescriptions | 2 | 2024 | 26 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 5 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2013 | 17 | 0.100 |
Why?
|
| Time Factors | 1 | 2014 | 176 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 20 | 0.100 |
Why?
|
| Liver Diseases | 1 | 2013 | 3 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2013 | 10 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2024 | 35 | 0.090 |
Why?
|
| Logistic Models | 2 | 2024 | 69 | 0.090 |
Why?
|
| Universities | 2 | 2022 | 80 | 0.080 |
Why?
|
| Students | 2 | 2023 | 122 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2024 | 3 | 0.060 |
Why?
|
| Inappropriate Prescribing | 1 | 2024 | 2 | 0.060 |
Why?
|
| Social Responsibility | 1 | 2024 | 9 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2024 | 13 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2024 | 131 | 0.050 |
Why?
|
| Comorbidity | 1 | 2024 | 49 | 0.050 |
Why?
|
| Medicare | 1 | 2024 | 79 | 0.050 |
Why?
|
| Decision Trees | 1 | 2023 | 9 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2023 | 47 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 17 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 20 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2023 | 3 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 55 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 350 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2020 | 8 | 0.040 |
Why?
|
| Anxiety | 1 | 2023 | 173 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 20 | 0.040 |
Why?
|
| Young Adult | 1 | 2024 | 850 | 0.040 |
Why?
|
| College Admission Test | 1 | 2020 | 3 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 31 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2020 | 5 | 0.040 |
Why?
|
| Network Meta-Analysis | 1 | 2020 | 1 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 4 | 0.040 |
Why?
|
| Hospitalization | 1 | 2019 | 38 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 3 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2016 | 3 | 0.030 |
Why?
|
| Intention | 1 | 2016 | 19 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 22 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2016 | 22 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 32 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 277 | 0.030 |
Why?
|